Details of Drug

Drug General Information (ID: D0724)
Drug Name	Givosiran
Drug Type	Small interfering RNA
Drug Synonymous	1639325-43-1; N-[1,3-Bis[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]-2-[[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]methyl]propan-2-yl]-12-[(2R,4R)-4-hydroxy-2-methylpyrrolidin-1-yl]-12-oxododecanamide; Fitusiran; Givlaari; Givosiran [INN]; Givosiran [USAN]; Givosiran [USAN:INN]; ALN-AS1; UNII-ROV204583W; ROV204583W; WHO 10280 Click to Show/Hide
Disease Class	5C58: Inborn porphyrin/heme metabolism error
Therapeutic Class	Metabolic Agents
Structure
Structure	3D Structure		2D Structure
Formula	C78H139N11O30
InChI	1S/C78H139N11O30/c1-50-42-54(96)43-89(50)65(104)26-12-10-8-6-5-7-9-11-25-64(103)88-78(47-111-39-27-61(100)82-33-19-30-79-58(97)22-13-16-36-114-75-66(85-51(2)93)72(108)69(105)55(44-90)117-75,48-112-40-28-62(101)83-34-20-31-80-59(98)23-14-17-37-115-76-67(86-52(3)94)73(109)70(106)56(45-91)118-76)49-113-41-29-63(102)84-35-21-32-81-60(99)24-15-18-38-116-77-68(87-53(4)95)74(110)71(107)57(46-92)119-77/h50,54-57,66-77,90-92,96,105-110H,5-49H2,1-4H3,(H,79,97)(H,80,98)(H,81,99)(H,82,100)(H,83,101)(H,84,102)(H,85,93)(H,86,94)(H,87,95)(H,88,103)/t50-,54-,55-,56-,57-,66-,67-,68-,69+,70+,71+,72-,73-,74-,75-,76-,77-/m1/s1
InChIKey	RUPXJRIDSUCQAN-PQNNUJSWSA-N
Canonical SMILES	CC1CC(CN1C(=O)CCCCCCCCCCC(=O)NC(COCCC(=O)NCCCNC(=O)CCCCOC2C(C(C(C(O2)CO)O)O)NC(=O)C)(COCCC(=O)NCCCNC(=O)CCCCOC3C(C(C(C(O3)CO)O)O)NC(=O)C)COCCC(=O)NCCCNC(=O)CCCCOC4C(C(C(C(O4)CO)O)O)NC(=O)C)O
External Link
	Pubchem ID	119058042
	CAS Number	1639325-43-1
	TTD ID	DF36DY

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM004 Affected intra/extra-hepatic metabolism AM005 Affected excretion pathways AM006 Pharmacodynamic additive effects BM017 CYP450 enzyme inhibition BM027 Decreased renal excretion due to nephrotoxicity BM055 Increased risk of hepatotoxicity BM072 Increased risk of nephrotoxicity
Relation Graph

Full list of drugs interacting with Givosiran
Affected intra/extra-hepatic metabolism
	CYP450 enzyme inhibition					Drug Num: 94
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0202		Brexpiprazole	C25H27N3O2S	11978813	Major		Inter Info	[1]
D0559		Eliglustat	C23H36N2O4	23652731	Major		Inter Info	[12], [13]
D1169		Oliceridine	C22H30N2O2S	66553195	Major		Inter Info	[27], [28]
D1299		Pirfenidone	C12H11NO	40632	Major		Inter Info	[30], [20], [31]
D1385		Rasagiline	C12H13N	3052776	Major		Inter Info	[30], [20], [32]
D1533		Tamoxifen	C26H29NO	2733526	Major		Inter Info	[33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [13], [59], [60], [61], [62], [63], [64], [65], [66]
D1574		Thioridazine	C21H26N2S2	5452	Major		Inter Info	[67], [68], [69]
D1596		Tizanidine	C9H8ClN5S	5487	Major		Inter Info	[70], [71], [72], [73], [74], [75], [76], [77]
D0011		Acetaminophen	C8H9NO2	1983	Moderate		Inter Info	[78]
D0043		Alosetron	C17H18N4O	2099	Moderate		Inter Info	[79]
D0072		Amoxapine	C17H16ClN3O	2170	Moderate		Inter Info	[78]
D0074		Amphetamine	C9H13N	3007	Moderate		Inter Info	[78]
D0084		Anagrelide	C10H7Cl2N3O	135409400	Moderate		Inter Info	[80]
D0105		Aripiprazole	C23H27Cl2N3O2	60795	Moderate		Inter Info	[81]
D0112		Asenapine	C17H16ClNO	3036780	Moderate		Inter Info	[82]
D0119		Atomoxetine	C17H21NO	54841	Moderate		Inter Info	[94], [95], [96]
D0157		Bendamustine	C16H21Cl2N3O2	65628	Moderate		Inter Info	[102]
D0231		Caffeine	C8H10N4O2	2519	Moderate		Inter Info	[78]
D0308		Cevimeline	C10H17NOS	83898	Moderate		Inter Info	[106]
D0323		Chlorpheniramine	C16H19ClN2	2725	Moderate		Inter Info	[78]
D0324		Chlorpromazine	C17H19ClN2S	2726	Moderate		Inter Info	[30], [20], [107]
D0361		Clomipramine	C19H23ClN2	2801	Moderate		Inter Info	[78]
D0370		Clozapine	C18H19ClN4	135398737	Moderate		Inter Info	[78]
D0379		Codeine	C18H21NO3	5284371	Moderate		Inter Info	[109], [110], [111], [112], [113], [114], [13], [115], [116], [117], [118], [119], [120]
D0398		Cyclobenzaprine	C20H21N	2895	Moderate		Inter Info	[78]
D0424		Darifenacin	C28H30N2O2	444031	Moderate		Inter Info	[121], [95]
D0446		Desipramine	C18H22N2	2995	Moderate		Inter Info	[78]
D0452		Deutetrabenazine	C19H27NO3	73437646	Moderate		Inter Info	[78]
D0457		Dexfenfluramine	C12H16F3N	66265	Moderate		Inter Info	[78]
D0466		Dextromethorphan	C18H25NO	5360696	Moderate		Inter Info	[30], [20], [122], [123], [95], [124]
D0467		Dextropropoxyphene	C22H29NO2	10100	Moderate		Inter Info	[78]
D0525		Doxepin	C19H21NO	667477	Moderate		Inter Info	[78]
D0528		Doxorubicin	C27H29NO11	31703	Moderate		Inter Info	[78]
D0529		Doxorubicin (liposomal)	C27H29NO11	31703	Moderate		Inter Info	[78]
D0539		Duloxetine	C18H19NOS	60835	Moderate		Inter Info	[125], [126], [127], [128]
D0641		Fenfluramine	C12H16F3N	3337	Moderate		Inter Info	[78]
D0664		Flecainide	C17H20F6N2O3	3356	Moderate		Inter Info	[78]
D0676		Fluoxetine	C17H18F3NO	3386	Moderate		Inter Info	[78]
D0678		Fluphenazine	C22H26F3N3OS	3372	Moderate		Inter Info	[78]
D0682		Flutamide	C11H11F3N2O3	3397	Moderate		Inter Info	[78]
D0687		Fluvoxamine	C15H21F3N2O2	5324346	Moderate		Inter Info	[78]
D0713		Gefitinib	C22H24ClFN4O3	123631	Moderate		Inter Info	[78]
D0750		Haloperidol	C21H23ClFNO2	3559	Moderate		Inter Info	[78]
D0791		Iloperidone	C24H27FN2O4	71360	Moderate		Inter Info	[78]
D0795		Imipramine	C19H24N2	3696	Moderate		Inter Info	[78]
D0916		Levobupivacaine	C18H28N2O	92253	Moderate		Inter Info	[20], [142]
D0927		Lidocaine	C14H22N2O	3676	Moderate		Inter Info	[78]
D0979		Maprotiline	C20H23N	4011	Moderate		Inter Info	[78]
D0987		Meclizine	C25H27ClN2	4034	Moderate		Inter Info	[78]
D1010		Mesoridazine	C21H26N2OS2	4078	Moderate		Inter Info	[78]
D1012		Metamfetamine	C10H15N	10836	Moderate		Inter Info	[78]
D1026		Methotrimeprazine	C19H24N2OS	72287	Moderate		Inter Info	[78]
D1046		Metoclopramide	C14H22ClN3O2	4168	Moderate		Inter Info	[78]
D1049		Metoprolol	C15H25NO3	4171	Moderate		Inter Info	[78]
D1054		Mexiletine	C11H17NO	4178	Moderate		Inter Info	[78]
D1061		Midodrine	C12H18N2O4	4195	Moderate		Inter Info	[78]
D1075		Mirtazapine	C17H19N3	4205	Moderate		Inter Info	[144], [145], [13], [146], [147]
D1109		Naproxen	C14H14O3	156391	Moderate		Inter Info	[78]
D1114		Nebivolol	C22H25F2NO4	71301	Moderate		Inter Info	[78]
D1158		Nortriptyline	C19H21N	4543	Moderate		Inter Info	[78]
D1166		Olanzapine	C17H20N4S	135398745	Moderate		Inter Info	[149], [150], [125], [151], [20], [152], [153], [154], [155], [156], [157], [158], [159], [160], [95], [161], [162], [163]
D1229		Paroxetine	C19H20FNO3	43815	Moderate		Inter Info	[78]
D1251		Pentoxifylline	C13H18N4O3	4740	Moderate		Inter Info	[166], [167]
D1302		Pitolisant	C17H26ClNO	9948102	Moderate		Inter Info	[20], [13], [168]
D1352		Promethazine	C17H20N2S	4927	Moderate		Inter Info	[78]
D1353		Propafenone	C21H27NO3	4932	Moderate		Inter Info	[78]
D1357		Propranolol	C16H21NO2	4946	Moderate		Inter Info	[78]
D1361		Protriptyline	C19H21N	4976	Moderate		Inter Info	[78]
D1378		Ramelteon	C16H21NO2	208902	Moderate		Inter Info	[169]
D1405		Riluzole	C8H5F3N2OS	5070	Moderate		Inter Info	[78]
D1413		Risperidone	C23H27FN4O2	5073	Moderate		Inter Info	[78]
D1415		Ritonavir	C37H48N6O5S2	392622	Moderate		Inter Info	[78]
D1422		Roflumilast	C17H14Cl2F2N2O3	449193	Moderate		Inter Info	[20], [173], [174]
D1427		Ropinirole	C16H24N2O	5095	Moderate		Inter Info	[175], [176]
D1428		Ropivacaine	C17H26N2O	175805	Moderate		Inter Info	[78]
D1534		Tamsulosin	C20H28N2O5S	129211	Moderate		Inter Info	[177], [178], [179], [13]
D1536		Tasimelteon	C15H19NO2	10220503	Moderate		Inter Info	[180]
D1560		Tetrabenazine	C19H27NO3	6018	Moderate		Inter Info	[78]
D1570		Theophylline	C7H8N4O2	2153	Moderate		Inter Info	[78]
D1571		Thiabendazole	C10H7N3S	5430	Moderate		Inter Info	[78]
D1585		Timolol	C13H24N4O3S	33624	Moderate		Inter Info	[78]
D1586		Timolol (ophthalmic)	C13H24N4O3S	33624	Moderate		Inter Info	[182], [183], [184]
D1616		Tramadol	C16H25NO2	33741	Moderate		Inter Info	[78]
D1624		Trazodone	C19H22ClN5O	5533	Moderate		Inter Info	[78]
D1647		Trimipramine	C20H26N2	5584	Moderate		Inter Info	[78]
D1673		Valbenazine	C24H38N2O4	24795069	Moderate		Inter Info	[78]
D1708		Vortioxetine	C18H22N2S	9966051	Moderate		Inter Info	[78]
D1711		Warfarin	C19H16O4	54678486	Moderate		Inter Info	[78]
D1721		Zileuton	C11H12N2O2S	60490	Moderate		Inter Info	[78]
D1728		Zolmitriptan	C16H21N3O2	60857	Moderate		Inter Info	[20], [199]
D0516		Donepezil	C24H29NO3	3152	Minor		Inter Info	[200], [13], [201], [202]
D0994		Melatonin	C13H16N2O2	896	Minor		Inter Info	[30]
D1383		Ranolazine	C24H33N3O4	56959	Minor		Inter Info	[203]
D1607		Tolterodine	C22H31NO	443879	Minor		Inter Info	[204], [205], [13]
Affected excretion pathways
	Decreased renal excretion due to nephrotoxicity					Drug Num: 5
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0576		Entecavir	C12H15N5O3	135398508	Moderate		Inter Info	[131]
D0668		Flucytosine	C4H4FN3O	3366	Moderate		Inter Info	[136]
D1193		Oxaliplatin	C8H14N2O4Pt	9887053	Moderate		Inter Info	[164]
D1241		Pemetrexed	C20H21N5O6	135410875	Moderate		Inter Info	[165]
D1543		Telbivudine	C10H14N2O5	159269	Moderate		Inter Info	[181]
Pharmacodynamic additive effects
	Increased risk of hepatotoxicity					Drug Num: 24
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0900		Leflunomide	C12H9F3N2O2	3899	Major		Inter Info	[22], [23], [24]
D0944		Lomitapide	C39H37F6N3O2	9853053	Major		Inter Info	[25]
D1073		Mipomersen	C230H324N67O122P19S19	118984467	Major		Inter Info	[26]
D1258		Pexidartinib	C20H15ClF3N5	25151352	Major		Inter Info	[29]
D1556		Teriflunomide	C12H9F3N2O2	54684141	Major		Inter Info	[22], [23], [24]
D0113		Asparaginase Erwinia chrysanthemi	NA	NA	Moderate		Inter Info	[83], [84], [85], [30], [20], [86], [87], [88], [89], [90], [91], [92], [93]
D0114		Asparaginase Escherichia coli	NA	NA	Moderate		Inter Info	[84], [30], [92]
D0149		Bedaquiline	C32H31BrN2O2	5388906	Moderate		Inter Info	[101]
D0199		Brentuximab vedotin	NA	NA	Moderate		Inter Info	[103]
D0232		Calaspargase pegol	NA	NA	Moderate		Inter Info	[84], [30], [92]
D0248		Cannabidiol	C21H30O2	644019	Moderate		Inter Info	[20], [104]
D0357		Clofarabine	C10H11ClFN5O3	119182	Moderate		Inter Info	[108]
D0554		Efavirenz	C14H9ClF3NO2	64139	Moderate		Inter Info	[129], [130]
D0584		Epirubicin	C27H29NO11	41867	Moderate		Inter Info	[30], [20], [132]
D0789		Idelalisib	C22H18FN7O	11625818	Moderate		Inter Info	[137]
D0826		Interferon beta-1a	NA	NA	Moderate		Inter Info	[138], [139], [140], [141]
D0827		Interferon beta-1b	NA	NA	Moderate		Inter Info	[138], [139], [140], [141]
D1025		Methotrexate	C20H22N8O5	126941	Moderate		Inter Info	[20], [143]
D1106		Naltrexone	C20H23NO4	5360515	Moderate		Inter Info	[148]
D1234		Pegaspargase	C14H19NO	436058	Moderate		Inter Info	[83], [84], [85], [30], [20], [86], [87], [88], [89], [90], [91], [92], [93]
D1239		Peginterferon beta-1a	NA	NA	Moderate		Inter Info	[138], [139], [140], [141]
D1389		Remdesivir	C27H35N6O8P	121304016	Moderate		Inter Info	[30], [20], [170], [171], [172]
D1589		Tioguanine	C5H5N5S	2723601	Moderate		Inter Info	[185], [186]
D1615		Trabectedin	C39H43N3O11S	108150	Moderate		Inter Info	[20], [187]
	Increased risk of nephrotoxicity					Drug Num: 76
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0335		Cidofovir	C8H14N3O6P	60613	Major		Inter Info	[2]
D0432		Deferasirox	C21H15N3O4	214348	Major		Inter Info	[3], [4]
D0472		Diatrizoate	C11H9I3N2O4	2140	Major		Inter Info	[5], [6], [7], [8], [9], [10], [11]
D0629		Everolimus	C53H83NO14	6442177	Major		Inter Info	[14], [15], [16]
D0761		Human botulinum neurotoxin A/B immune globulin	NA	NA	Major		Inter Info	[17], [18], [19]
D0763		Human cytomegalovirus immune globulin	NA	NA	Major		Inter Info	[17], [18], [19]
D0765		Human immunoglobulin G (intravenous)	NA	NA	Major		Inter Info	[17], [18], [19]
D0768		Human Rho(D) immune globulin	NA	NA	Major		Inter Info	[17], [18], [19]
D0805		Inotersen	C230H318N69O121P19S19	121492004	Major		Inter Info	[20], [21]
D0831		Iodipamide	C20H14I6N2O6	3739	Major		Inter Info	[7], [8], [9]
D0832		Iodixanol	C35H44I6N6O15	3724	Major		Inter Info	[5], [6], [7], [8], [9], [10], [11]
D0833		Iohexol	C19H26I3N3O9	3730	Major		Inter Info	[5], [6], [7], [8], [9], [10], [11]
D0834		Iopamidol	C17H22I3N3O8	65492	Major		Inter Info	[5], [6], [7], [8], [9], [10], [11]
D0836		Iopromide	C18H24I3N3O8	3736	Major		Inter Info	[7], [8], [9]
D0837		Iothalamic acid	C11H9I3N2O4	3737	Major		Inter Info	[7], [8], [9]
D0838		Ioversol	C18H24I3N3O9	3741	Major		Inter Info	[5], [6], [7], [8], [9], [10], [11]
D0839		Ioxilan	C18H24I3N3O8	3743	Major		Inter Info	[7], [8], [9]
D1476		Sirolimus	C51H79NO13	5284616	Major		Inter Info	[14], [15], [16]
D1526		Tacrolimus	C44H69NO12	445643	Major		Inter Info	[14], [15], [16]
D1549		Temsirolimus	C56H87NO16	6918289	Major		Inter Info	[14], [15], [16]
D0022		Acyclovir	C8H11N5O3	135398513	Moderate		Inter Info	[30], [20]
D0056		Amikacin	C22H43N5O13	37768	Moderate		Inter Info	[30], [20]
D0057		Amikacin (liposome)	C22H43N5O13	37768	Moderate		Inter Info	[30], [20]
D0075		Amphotericin B	C47H73NO17	5280965	Moderate		Inter Info	[30], [20]
D0076		Amphotericin B (cholesteryl sulfate)	C47H73NO17	5280965	Moderate		Inter Info	[30], [20]
D0077		Amphotericin B (lipid complex)	C47H73NO17	5280965	Moderate		Inter Info	[30], [20]
D0078		Amphotericin B (liposomal)	C47H73NO17	5280965	Moderate		Inter Info	[30], [20]
D0145		Balsalazide	C17H15N3O6	54585	Moderate		Inter Info	[97], [98], [99], [100]
D0190		Bleomycin	C55H84N17O21S3+	5360373	Moderate		Inter Info	[30], [20]
D0252		Capreomycin	C50H88N28O15	3000502	Moderate		Inter Info	[30], [8], [105]
D0274		Cefamandole	C18H18N6O5S2	456255	Moderate		Inter Info	[30], [20]
D0276		Cefazolin	C14H14N8O4S3	33255	Moderate		Inter Info	[30], [20]
D0279		Cefepime	C19H24N6O5S2	5479537	Moderate		Inter Info	[30], [20]
D0281		Cefixime	C16H15N5O7S2	5362065	Moderate		Inter Info	[30], [20]
D0284		Cefoperazone	C25H27N9O8S2	44187	Moderate		Inter Info	[30], [20]
D0285		Cefotaxime	C16H17N5O7S2	5742673	Moderate		Inter Info	[30], [20]
D0286		Cefotetan	C17H17N7O8S4	53025	Moderate		Inter Info	[30], [20]
D0287		Cefoxitin	C16H17N3O7S2	441199	Moderate		Inter Info	[30], [20]
D0288		Cefpodoxime	C15H17N5O6S2	6335986	Moderate		Inter Info	[30], [20]
D0289		Cefprozil	C18H19N3O5S	5281006	Moderate		Inter Info	[30], [20]
D0290		Cefradine	C16H19N3O4S	38103	Moderate		Inter Info	[30], [20]
D0292		Ceftazidime	C22H22N6O7S2	5481173	Moderate		Inter Info	[30], [20]
D0297		Cefuroxime	C16H16N4O8S	5479529	Moderate		Inter Info	[30], [20]
D0312		Chlorambucil	C14H19Cl2NO2	2708	Moderate		Inter Info	[30], [20]
D0341		Ciprofloxacin	C17H18FN3O3	2764	Moderate		Inter Info	[30], [20]
D0344		Cisplatin	Cl2H6N2Pt	5702198	Moderate		Inter Info	[30], [20]
D0354		Clindamycin	C18H33ClN2O5S	446598	Moderate		Inter Info	[30], [20]
D0400		Cyclophosphamide	C7H15Cl2N2O2P	2907	Moderate		Inter Info	[30], [20]
D0402		Cyclosporine	C62H111N11O12	5284373	Moderate		Inter Info	[30], [20]
D0421		Daptomycin	C72H101N17O26	16134395	Moderate		Inter Info	[20]
D0608		Estramustine	C23H31Cl2NO3	259331	Moderate		Inter Info	[30], [20]
D0623		Etidronic acid	C2H8O7P2	3305	Moderate		Inter Info	[133], [134], [135]
D0704		Furosemide	C12H11ClN2O5S	3440	Moderate		Inter Info	[30], [20]
D0718		Gentamicin	C21H43N5O7	3467	Moderate		Inter Info	[30], [20]
D0790		Ifosfamide	C7H15Cl2N2O2P	3690	Moderate		Inter Info	[30], [20]
D0876		Kanamycin	C18H36N4O11	6032	Moderate		Inter Info	[30], [20]
D0996		Melphalan	C13H18Cl2N2O2	460612	Moderate		Inter Info	[30], [20]
D1009		Mesalazine	C7H7NO3	4075	Moderate		Inter Info	[98], [99], [100]
D1030		Methoxyflurane	C3H4Cl2F2O	4116	Moderate		Inter Info	[20]
D1102		Nalidixic acid	C12H12N2O3	4421	Moderate		Inter Info	[30], [20]
D1120		Neomycin	C23H46N6O13	8378	Moderate		Inter Info	[30], [20]
D1126		Netilmicin	C21H41N5O7	441306	Moderate		Inter Info	[30], [20]
D1138		Nimodipine	C21H26N2O7	4497	Moderate		Inter Info	[30], [20]
D1173		Olsalazine	C14H10N2O6	22419	Moderate		Inter Info	[97], [98], [99], [100]
D1217		Pamidronic acid	C3H11NO7P2	4674	Moderate		Inter Info	[133], [134], [135]
D1246		Pentamidine	C19H24N4O2	4735	Moderate		Inter Info	[30], [20]
D1304		Plazomicin	C25H48N6O10	42613186	Moderate		Inter Info	[30], [20]
D1507		Streptomycin	C21H39N7O12	19649	Moderate		Inter Info	[30], [20]
D1516		Sulfamethoxazole	C10H11N3O3S	5329	Moderate		Inter Info	[30], [20]
D1517		Sulfasalazine	C18H14N4O5S	5339	Moderate		Inter Info	[97], [98], [99], [100]
D1597		Tobramycin	C18H37N5O9	36294	Moderate		Inter Info	[30], [20]
D1645		Trimethoprim	C14H18N4O3	5578	Moderate		Inter Info	[30], [20]
D1667		Uracil mustard	C8H11Cl2N3O2	6194	Moderate		Inter Info	[30], [20]
D1672		Valaciclovir	C13H20N6O4	135398742	Moderate		Inter Info	[20], [188]
D1680		Vancomycin	C66H75Cl2N9O24	14969	Moderate		Inter Info	[30], [8], [105]
D1727		Zoledronic acid	C5H10N2O7P2	68740	Moderate		Inter Info	[189], [190], [191], [134], [192], [193], [194], [195], [196], [197], [135], [198]

References
1	Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
2	Product Information. Vistide (cidofovir). Gilead Sciences, Foster City, CA.
3	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
4	Rafat C, Fakhouri F, Ribeil JA, Delarue R, Le Quintrec M "Fanconi Syndrome Due to Deferasirox." Am J Kidney Dis (2009):. [PMID: 19493602]
5	Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
6	Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56. [PMID: 2407013]
7	Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74. [PMID: 20502171]
8	Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7. [PMID: 25652747]
9	Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001. [PMID: 19445797]
10	Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6. [PMID: 22174040]
11	van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70. [PMID: 16137385]
12	Product Information. Cerdelga (eliglustat). Genzyme Corporation, Cambridge, MA.
13	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
14	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
15	Product Information. Rapamune (sirolimus) Wyeth-Ayerst Laboratories, Philadelphia, PA.
16	Sheiner PA, Mor E, Chodoff L, Glabman S, Emre S, Schwartz ME, Miller CM "Acute renal, failure associated with the use of ibuprofen in two liver transplant recipients on FK506." Transplantation 57 (1994): 1132-3. [PMID: 7513099]
17	Guo X, Nzerue C "How to prevent, recognize, and treat drug-induced nephrotoxicity.".
18	Centers for Disease Control and Prevention (CDC). Renal insufficiency and failure associated with immune globulin intravenous therapy--United States, 1985-1998.?MMWR Morb Mortal Wkly Rep. 1999;48(24):518-521. [PMID: 10401909]
19	Product Information. BabyBIG (botulism immune globulin). FFF Enterprises, Temecula, CA.
20	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
21	Product Information. Tegsedi (inotersen). Akcea Therapeutics, Cambridge, MA.
22	Canadian Pharmacists Association.
23	EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
24	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
25	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
26	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
27	Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
28	Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
29	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
30	Cerner Multum, Inc. "Australian Product Information.".
31	Product Information. Esbriet (pirfenidone). Intermune Inc, Brisbane, CA.
32	Product Information. Azilect (rasagiline). Teva Pharmaceuticals USA, North Wales, PA.
33	Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51. [PMID: 11304901]
34	Aubert RE, Stanek EJ, Yao J, et al "Increased risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors".
35	Bonanni B, Macis D, Maisonneuve P, et al. "Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial." J Clin Oncol 24 (2006): 3708-9. [PMID: 16877740]
36	Borges S, Desta Z, Li L, et al. "Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment." Clin Pharmacol Ther 80 (2006): 61-74. [PMID: 16815318]
37	Borgna JL, Rochefort H "Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues." J Biol Chem 256 (1981): 859-68. [PMID: 7451477]
38	Brauch H, Murdter TE, Eichelbaum M, Schwab M "Pharmacogenomics of tamoxifen therapy." Clin Chem 55 (2009): 1770-82. [PMID: 19574470]
39	Coller JK, Krebsfaenger N, Klein K, et al. "The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver." Br J Clin Pharmacol 54 (2002): 157-167. [PMID: 12207635]
40	Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE "The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes." Br J Clin Pharmacol 34 (1992): 262-5. [PMID: 1389951]
41	Dehal SS, Kupfer D "CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver." Cancer Res 57 (1997): 3402-6. [PMID: 9270005]
42	Desta Z, Flockhart DA "Germline pharmacogenetics of tamoxifen response: have we learned enough?" J Clin Oncol 25 (2007): 5147-9. [PMID: 18024859]
43	Desta Z, Ward BA, Soukhova NV, Flockhart DA "Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6." J Pharmacol Exp Ther (2004):. [PMID: 15159443]
44	Dezentje VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H "Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer." Clin Cancer Res 15 (2009): 15-21. [PMID: 19118028]
45	Gaston C, Kolesar J "Clinical Significance of CYP2D6 Polymorphisms and Tamoxifen in Women with Breast Cancer." Clin Adv Hematol Oncol 6 (2008): 825-33. [PMID: 19194367]
46	Goetz MP, Kamal A, Ames MM "Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response." Clin Pharmacol Ther (2007):. [PMID: 17882159]
47	Goetz MP, Loprinzi CL "A hot flash on tamoxifen metabolism." J Natl Cancer Inst 95 (2003): 1734-5. [PMID: 14652227]
48	Goetz MP, Rae JM, Suman VJ, et al. "Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes." J Clin Oncol 23 (2005): 9312-8. [PMID: 16361630]
49	Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M "Drug interactions and pharmacogenomics in the treatment of breast cancer and depression." Am J Psychiatry 165 (2008): 1251-5. [PMID: 18829880]
50	Jin Y, Desta Z, Stearns V, et al. "CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment." J Natl Cancer Inst 97 (2005): 30-9. [PMID: 15632378]
51	Johnson MD, Zuo H, Lee KH, et al. "Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen." Breast Cancer Res Treat 85 (2004): 151-9. [PMID: 15111773]
52	Jordan VC "Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance." Breast Cancer Res Treat 2 (1982): 123-38. [PMID: 6184101]
53	Jordan VC, Collins MM, Rowsby L, Prestwich G "A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity." J Endocrinol 75 (1977): 305-16. [PMID: 591813]
54	Lash TL, Pedersen L, Cronin-Fenton D, et al "Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram." Br J Cancer 99 (2008): 616-21. [PMID: 20385012]
55	Lehmann D, Nelsen J, Ramanath V, Newman N, Duggan D, Smith A "Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition." J Clin Pharmacol 44 (2004): 861-5. [PMID: 15286089]
56	Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J "Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer." J Clin Oncol 25 (2007): 3837-45. [PMID: 17761971]
57	McCaffrey P "Genetics and drug interactions affect tamoxifen metabolism." Lancet Oncol 6 (2005): 72. [PMID: 15704296]
58	Ponzone R, Biglia N, Sismondi P "Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 96 (2004): 883-4 author reply 884-5. [PMID: 15173274]
59	Rochat B "Role of cytochrome p450 activity in the fate of anticancer agents and in drug resistance : focus on tamoxifen, Paclitaxel and imatinib metabolism." Clin Pharmacokinet 44 (2005): 349-66. [PMID: 15828850]
60	Schroth W, Antoniadou L, Fritz P, et al. "Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes." J Clin Oncol 25 (2007): 5187-93. [PMID: 18024866]
61	Stearns V, Johnson MD, Rae JM, et al. "Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 95 (2003): 1758-64. [PMID: 14652237]
62	Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S "Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer." Breast Cancer Res 9 (2007): R7. [PMID: 17244352]
63	Wegman P, Vainikka L, Stal O, et al "Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients." Breast Cancer Res 7 (2005): R284-90. [PMID: 15987423]
64	Young D "Genetics examined in tamoxifen's effectiveness: recurrence warning urged for labeling." Am J Health Syst Pharm 63 (2006): 2286, 2296. [PMID: 17105997]
65	Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM "Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen." Drug Metab Dispos 30 (2002): 869-74. [PMID: 12124303]
66	Ratliff B, Dietze EC, Bean GR, Moore C, Wanko S, Seewaldt VL "Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 96 (2004): 883 author reply 884-5. [PMID: 15173275]
67	Carrillo JA, Ramos SI, Herraiz AG, Llerena A, Agundez JAG, Berecz R, Duran M, Benitez J "Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients." J Clin Psychopharmacol 19 (1999): 494-9. [PMID: 10587283]
68	Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82. [PMID: 11691681]
69	Greendyke RM, Gulya A "Effect of pindolol administration on serum levels of thioridazine, haloperidol, phenytoin, and phenobarbital." J Clin Psychiatry 49 (1988): 105-7. [PMID: 3346197]
70	Granfors MT, Backman JT, Laitila J, Neuvonen PJ "Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro." Br J Clin Pharmacol 57 (2004): 349-53. [PMID: 14998432]
71	Granfors MT, Backman JT, Neuvonen M, Ahonen J, Neuvonen PJ "Fluvoxamine drastically increases concentrations and effects of tizanidine: A potentially hazardous interaction." Clin Pharmacol Ther 75 (2004): 331-41. [PMID: 15060511]
72	Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ "Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism." Clin Pharmacol Ther 76 (2004): 598-606. [PMID: 15592331]
73	Momo K, Doki K, Hosono H, Homma M, Kohda Y "Drug interaction of tizanidine and fluvoxamine." Clin Pharmacol Ther 76 (2004): 509-10. [PMID: 15536467]
74	Momo K, Homma M, Kohda Y, Ohkoshi N, Yoshizawa T, Tamaoka A "Drug interaction of tizanidine and ciprofloxacin: Case report." Clin Pharmacol Ther 80 (2006): 717-9. [PMID: 17178273]
75	Product Information. Vioxx (rofecoxib). Merck & Co, Inc, West Point, PA.
76	Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
77	Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
78	Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
79	Product Information. Lotronex (alosetron). Glaxo Wellcome, Research Triangle Park, NC.
80	Product Information. Agrylin (anagrelide). Roberts Pharmaceutical Corporation, Eatontown, NJ.
81	Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
82	Product Information. Saphris (asenapine). Schering-Plough Corporation, Kenilworth, NJ.
83	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
84	Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahenbuhl S "Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase." Digestion 74 (2006): epub. [PMID: 16988508]
85	Cerner Multum, Inc "ANVISA Bulario Eletrnico.".
86	Christ TN, Stock W, Knoebel RW "Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen." J Oncol Pharm Pract 24 (2018): 299-308. [PMID: 28355969]
87	Jenkins R, Perlin E "Severe hepatotoxicity from Escherichia coli L-asparaginase." J Natl Med Assoc 79 (1987): 775-9. [PMID: 3305969]
88	Lu G, Karur V, Herrington JD, Walker MG "Successful treatment of pegaspargase-induced acute hepatotoxicity with vitamin B complex and L-carnitine" Proc (Bayl Univ Med Cent) 29 (2016): 46-7. [PMID: 26722167]
89	Product Information. Asparlas (calaspargase pegol). Servier, Boston, MA.
90	Product Information. Elspar (asparaginase). Merck & Co, Inc, West Point, PA.
91	Product Information. Erwinaze (asparaginase Erwinia chrysanthemi). EUSA Pharma, Newtown, PA.
92	Product Information. Oncaspar (pegaspargase). Rhone-Poulenc Rorer, Collegeville, PA.
93	Burke PW, Aldoss I, Lunning MA, et.al "High-grade PEGylated asparaginase-related hepatotoxicity occurrence in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not necessarily predict recurrent hepatotoxicity in subsequent cycles." Blood 122 (2013): 2671. [PMID: 29407583]
94	Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, Witcher JW "Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics." J Clin Pharmacol 42 (2002): 1219-27. [PMID: 12412820]
95	Product Information. Qelbree (viloxazine). Supernus Pharmaceuticals Inc, Rockville, MD.
96	Product Information. Strattera (atomoxetine). Lilly, Eli and Company, Indianapolis, IN.
97	Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
98	Product Information. Canasa (mesalamine (5-aminosalicylic acid)). Axcan Scandipharm Inc, Birmingham, AL.
99	Product Information. Lialda (mesalamine (5-aminosalicylic acid)). Shire US Inc, Florence, KY.
100	Schreiber S. Hamling J, Zehnter E, et al "Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate." Gut 40 (1997): 761-6. [PMID: 9245930]
101	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
102	Product Information. Treanda (bendamustine). Cephalon Inc, West Chester, PA.
103	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
104	Product Information. Epidiolex (cannabidiol). Greenwich Biosciences Inc, Carlsbad, CA.
105	Product Information. Vancocin (vancomycin). Lilly, Eli and Company, Indianapolis, IN.
106	Product Information. Evoxac (cevimeline) Daiichi Pharmaceuticals, Fort lee, NJ.
107	Wojcikowski J, Boksa J, Daniel WA "Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines." Biochem Pharmacol 80 (2010): 1252-9. [PMID: 20615392]
108	Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
109	Caraco Y, Sheller J, Wood AJJ "Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects." J Pharmacol Exp Ther 290 (1999): 413-22. [PMID: 10381807]
110	Caraco Y, Sheller J, Wood JJ "Pharmacogenetic determination of the effects of codeine and prediction of drug interactions." J Pharmacol Exp Ther 278 (1996): 1165-74. [PMID: 8819499]
111	Desmeules J, Dayer P, Gascon MP, Magistris M "Impact of genetic and environmental factors on codeine analgesia." Clin Pharmacol Ther 45 (1989): 122. [PMID: 1782973]
112	Desmeules J, Gascon MP, Dayer P, Magistris M "Impact of environmental and genetic factors on codeine analgesia." Eur J Clin Pharmacol 41 (1991): 23-6. [PMID: 1782973]
113	Hersh EV, Moore PA "Drug interactions in dentistry: the importance of knowing your CYPs." J Am Dent Assoc 135 (2004): 298-311. [PMID: 15058617]
114	Poulsen L, Brosen K, Srendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH "Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects." Eur J Clin Pharmacol 51 (1996): 289-95. [PMID: 9010701]
115	Sindrup SH, Arendt-Nielsen L, Brosen K, et al "The effect of quinidine on the analgesic effect of codeine." Eur J Clin Pharmacol 42 (1992): 587-92. [PMID: 1623898]
116	Sindrup SH, Brosen K, Bjerring P, et al. "Codeine increases pain threshold to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine." Clin Pharmacol Ther 49 (1991): 686-93. [PMID: 2249379]
117	Sindrup SH, Hofmann U, Asmussen J, Mikus G, Brosen K, Nielsen F, Ingwersen SH, Broen Christensen C "Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake." Eur J Clin Pharmacol 49 (1996): 503-9. [PMID: 8706777]
118	Thorn CF, Klein TE, Altman RB "Codeine and morphine pathway." Pharmacogenet Genomics 19 (2009): 556-8. [PMID: 19512957]
119	Vevelstad M, Pettersen S, Tallaksen C, Brors O "O-demethylation of codeine to morphine inhibited by low-dose levomepromazine." Eur J Clin Pharmacol 65 (2009): 795-801. [PMID: 19308365]
120	Zhou SF "Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II." Clin Pharmacokinet 48 (2009): 761-804. [PMID: 19902987]
121	Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
122	Funck-Brentano C, Jacqz-Aigrain E, Leenhardt A, Roux A, Poirier JM, Jaillon P "Influence of amiodarone on genetically determined drug metabolism in humans." Clin Pharmacol Ther 50 (1991): 259-66. [PMID: 1914360]
123	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
124	Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
125	Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S "Fluvoxamine is a potent inhibitor of cytochrome P4501A2." Biochem Pharmacol 45 (1993): 1211-4. [PMID: 8466541]
126	Martinez C, Albet C, Agundez JA, et al. "Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists." Clin Pharmacol Ther 65 (1999): 369-76. [PMID: 10223772]
127	Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
128	Uwe F, Strobl G, Manaut F, et al "Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isofaorm CYP1A2." Mol Pharmacol 43 (1993): 191-9. [PMID: 8429824]
129	Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
130	Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
131	Product Information. Baraclude (entecavir). Bristol-Myers Squibb, Princeton, NJ.
132	Product Information. Ellence (epirubicin) Pharmacia and Upjohn, Kalamazoo, MI.
133	Chang JT, Green L, Beitz J "Renal failure with the use of zoledronic acid." N Engl J Med 349 (2003): 1676-9 discussion 1676-9. [PMID: 14573746]
134	Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG "Effects of intravenous diphosphonates on renal function." Lancet 1 (1983): 1328. [PMID: 6134112]
135	Product Information. Zometa (zoledronic acid). Novartis Pharmaceuticals, East Hanover, NJ.
136	Product Information. Ancobon (flucytosine). Roche Laboratories, Nutley, NJ.
137	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
138	Product Information. Avonex (interferon beta-1a). Biogen, Cambridge, MA.
139	Product Information. Betaseron (interferon beta-1b). Berlex, Richmond, CA.
140	Product Information. Plegridy (peginterferon beta-1a). Biogen Idec Inc, Cambridge, MA.
141	Product Information. Rebif (interferon beta-1a). Serono Laboratories Inc, Norwell, MA.
142	Product Information. Chirocaine (levobupivacaine) Organon, West Orange, NJ.
143	Product Information. Methotrexate (methotrexate). Lederle Laboratories, Wayne, NJ.
144	Okubo M, Murayama N, Miura J, Chiba Y, Yamazaki H "Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients." Biochem Pharmacol 93 (2015): 104-9. [PMID: 25475885]
145	Product Information. Remeron (mirtazapine). Organon, West Orange, NJ.
146	Sitsen JM, Maris FA, Timmer CJ "Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects." Eur J Clin Pharmacol 56 (2000): 389-94. [PMID: 11009047]
147	Stormer E, von Moltke LL, Shader RI, Greenblatt DJ "Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4" Drug Metab Dispos 28 (2000): 1168-75. [PMID: 10997935]
148	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
149	Albers LJ, Ozdemir V, Marder SR, et al. "Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy." J Clin Psychopharmacol 25 (2005): 170-174. [PMID: 15738749]
150	Bergemann N, Frick A, Parzer P, Kopitz J "Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients." Pharmacopsychiatry 37 (2004): 63-8. [PMID: 15048613]
151	Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM "Olanzapine. Pharmacokinetic and pharmacodynamic profile." Clin Pharmacokinet 37 (1999): 177-93. [PMID: 10511917]
152	Chiu CC, Lane HY, Huang MC, et al. "Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia." J Clin Pharmacol 44 (2004): 1385-90. [PMID: 15545309]
153	de Jong J, Hoogenboom B, van Troostwijk LD, de Haan L "Interaction of olanzapine with fluvoxamine." Psychopharmacology (Berl) 155 (2001): 219-20. [PMID: 11401013]
154	Desai HD, Seabolt J, Jann MW "Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective." CNS Drugs 15 (2001): 469-94. [PMID: 11524025]
155	Gex-Fabry M, Balant-Gorgia AE, Balant LP "Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication." Ther Drug Monit 25 (2003): 46-53. [PMID: 12548144]
156	Gossen D, de Suray JM, Vandenhende F, Onkelinx C, Gangji D "Influence of fluoxetine on olanzapine pharmacokinetics." AAPS PharmSci 4 (2002): E11. [PMID: 12102620]
157	Hiemke C, Peled A, Jabarin M, et al. "Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects." J Clin Psychopharmacol 22 (2002): 502-6. [PMID: 12352274]
158	Letsas KP, Sideris A, Kounas SP, Efremidis M, Korantzopoulos P, Kardaras F "Drug-induced QT interval prolongation after ciprofloxacin administration in a patient receiving olanzapine." Int J Cardiol 109 (2006): 273-4. [PMID: 15935493]
159	Markowitz JS, DeVane CL "Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentration." J Clin Psychopharmacol 19 (1999): 289-91. [PMID: 10350045]
160	Product Information. Lybalvi (olanzapine-samidorphan). Alkermes, Inc, Cambridge, MA.
161	Product Information. Zyprexa (olanzapine). Lilly, Eli and Company, Indianapolis, IN.
162	Wang CY, Zhang ZJ, Li WB, et al. "The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers." J Clin Pharmacol 44 (2004): 785-92. [PMID: 15199083]
163	Weigmann H, Gerek S, Zeisig A, Muller M, Hartter S, Hiemke C "Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service." Ther Drug Monit 23 (2001): 410-3. [PMID: 11477325]
164	Product Information. Eloxatin (oxaliplatin). Sanofi Winthrop Pharmaceuticals, New York, NY.
165	Product Information. Alimta (pemetrexed). Lilly, Eli and Company, Indianapolis, IN.
166	Magnusson M, Bergstrand IC, Bjorkman S, Heijl A, Roth B, Hoglund P "A placebo-controlled study of retinal blood flow changes by pentoxifylline and metabolites in humans." Br J Clin Pharmacol 61 (2006): 138-47. [PMID: 16433868]
167	Product Information. Trental (pentoxifylline). Hoechst Marion-Roussel Inc, Kansas City, MO.
168	Product Information. Wakix (pitolisant). Harmony Biosciences, LLC, Plymouth Meeting, PA.
169	Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
170	European Medicines Agency "Summary on compassionate use. Remdesivir Gilead.".
171	Gilead Sciences, Inc "About Remdesivir.".
172	US Food and Drug Administration "Fact sheet for health care providers emergency use authorization (EUA) of remdesivir (GS-5734TM)".
173	Product Information. Daliresp (roflumilast). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
174	Product Information. Daxas (roflumilast). Nycomed Inc, Princeton, NJ.
175	Product Information. Noroxin (norfloxacin). Merck & Co, Inc, West Point, PA.
176	Product Information. Requip (ropinirole). SmithKline Beecham, Philadelphia, PA.
177	Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
178	Kamimura H, Oishi S, Matsushima H, et al. "Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes." Xenobiotica 28 (1998): 909-22. [PMID: 9849639]
179	Product Information. Flomax (tamsulosin). Boehringer-Ingelheim, Ridgefield, CT.
180	Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
181	Product Information. Tyzeka (telbivudine). IDEC Pharmaceuticals Corporation, San Diego, CA.
182	Edeki TI, He HB, Wood AJJ "Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops: potential for oral-ophthalmic drug interaction." JAMA 274 (1995): 1611-3. [PMID: 7474246]
183	Fraunfelder FT, Fraunfelder FW Randall JA "Drug-Induced Ocular Side Effects 5th" Boston, MA: Butterworth-Heinemann (2001):.
184	Lewis RV, Lennard MS, Jackson PR, Tucker GT, Ramsay LE, Woods HF "Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics." Br J Clin Pharmacol 19 (1985): 329-33. [PMID: 2859048]
185	Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
186	Product Information. Tabloid (thioguanine). Prasco Laboratories, Cincinnati, OH.
187	Product Information. Yondelis (trabectedin). Janssen Pharmaceuticals, Titusville, NJ.
188	Product Information. Valtrex (valacyclovir). Glaxo Wellcome, Research Triangle Park, NC.
189	Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D "Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity." Am J Kidney Dis 41 (2003): E18. [PMID: 12778436]
190	Chang JT, Green L, Beitz J "Renal failure with the use of zoledronic acid." N Engl J Med 349 (2003): 1676-9 discussion 1676-9. [PMID: 14573746]
191	Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D "Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases." Nephron 89 (2001): 467-8. [PMID: 11721169]
192	Lockridge L, Papac RJ, Perazella MA "Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis." Am J Kidney Dis 40 (2002): E2. [PMID: 12087588]
193	Markowitz GS, Fine PL, Stack JI, et al. "Toxic acute tubular necrosis following treatment with zoledronate (Zometa)." Kidney Int 64 (2003): 281-289. [PMID: 12787420]
194	Osullivan TL, Akbari A, Cadnapaphornchai P "Acute renal failure associated with the administration of parenteral etidronate." Ren Fail 16 (1994): 767-73. [PMID: 7899588]
195	Product Information. Aredia (pamidronate). Novartis Pharmaceuticals, East Hanover, NJ.
196	Product Information. Boniva (ibandronate). Roche Laboratories, Nutley, NJ.
197	Product Information. Ostac (clodronate). Hoffmann-La Roche Limited, Mississauga, IA.
198	Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M "Acute renal failure and alendronate." Nephrol Dial Transplant 12 (1997): 2797-8. [PMID: 9430905]
199	Multum Information Services, Inc. Expert Review Panel.
200	Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
201	Rojas-Fernandez C, Fisher C "Drug interactions and donepezil." J Am Geriat Soc 40 (2000): 597-8. [PMID: 10811561]
202	Tiseo PJ, Perdomo CA, Friedhoff LT "Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses." Br J Clin Pharmacol 46 (1998): 30-4. [PMID: 9839763]
203	Product Information. Ranexa (ranolazine). Calmoseptine Inc, Huntington Beach, CA.
204	Brynne N, Svanstrom C, AbergWistedt A, Hallen B, Bertilsson L "Fluoxetine inhibits the metabolism of tolterodin-pharmacokinetic implications and proposed clinical relevance." Br J Clin Pharmacol 48 (1999): 553-63. [PMID: 10583026]
205	Product Information. Detrol (tolterodine). Pharmacia and Upjohn, Kalamazoo, MI.

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence